Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Andrew Scott Liss

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4040-9172; OpenAlex author ID A5082729431; NIH RePORTER profile ID 11099999. Sources: OpenAlex.

Their work

Papers
32 (first author 1, last author 12)
Trials
0
Grants
3
Labs led
1
Collaborators
137
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: 6 papers, 1 grant · 2021: 2 papers · 2022: 6 papers · 2023: none · 2024: 4 papers · 2025: 2 papers · 2026: 4 papers, 2 grants

Papers 32

  1. Driving tumor-associated macrophages to a CXCL9Hi/SPP1Low phenotype eliminates pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2026.102938↗
  2. Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition. Co-author DOI 10.1158/1078-0432.ccr-25-1788↗
  3. Photodynamic priming enhances anti-PD1 therapy responses in patient-derived pancreatic cancer organoid immune cocultures. Co-author DOI 10.3389/fimmu.2026.1805948↗
  4. A near-complete human pancreatic cancer genome Co-author DOI 10.64898/2026.05.01.722316↗
  5. Highly multiplexed digital PCR assay for simultaneous quantification of variant allele frequencies and copy number alterations of KRAS and GNAS in pancreatic c… Co-author DOI 10.1002/1878-0261.70011↗
  6. Collagen XVII Promotes Pancreatic Ductal Adenocarcinoma Tumor Growth through Regulation of PIK3R5. Last author DOI 10.1158/2767-9764.crc-24-0392↗
  7. Disruption of cellular plasticity by repeat RNAs in human pancreatic cancer. Co-author DOI 10.1016/j.cell.2024.09.024↗
  8. Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-3548↗
  9. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma. Co-author DOI 10.1158/1078-0432.ccr-23-3841↗
  10. Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-23-0489↗
  11. Mutant GNAS limits tumor aggressiveness in established pancreatic cancer via antagonizing the KRAS-pathway. Co-author DOI 10.1007/s00535-021-01846-4↗
  12. Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy. Last author DOI 10.1007/s00535-022-01915-2↗
  13. Correction to: Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy. Last author DOI 10.1007/s00535-022-01922-3↗
  14. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Co-author DOI 10.1038/s41588-022-01134-8↗
  15. A Lesson in Transcriptional Plasticity: Classical Identity Is Silenced, but Not Lost, in Pancreatic Ductal Adenocarcinoma Cell Lines. Last author DOI 10.1053/j.gastro.2022.07.005↗
  16. Single-EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer. Co-author DOI 10.1126/sciadv.abm3453↗
  17. Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer. Co-author DOI 10.1002/bjs.12003↗
  18. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-20-1039↗
  19. Hedgehog signaling promotes angiogenesis directly and indirectly in pancreatic cancer. Last author DOI 10.1007/s10456-020-09725-x↗
  20. Primary and Metastatic Pancreatic Cancer Cells Exhibit Differential Migratory Potentials. Last author DOI 10.1097/mpa.0000000000001459↗
  21. Single-nucleus and spatial transcriptomics of archival pancreatic cancer reveals multi-compartment reprogramming after neoadjuvant treatment Co-author DOI 10.1101/2020.08.25.267336↗
  22. Neoplastic-Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer. Last author DOI 10.1158/1541-7786.mcr-20-0439↗
  23. A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-020-02414-9↗
  24. FOLFIRINOX Versus Gemcitabine-based Therapy for Pancreatic Ductal Adenocarcinoma: Lessons from Patient-derived Cell Lines. Last author DOI 10.21873/anticanres.14355↗
  25. Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer. Co-author DOI 10.1016/j.cell.2019.05.012↗
  26. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.1914915116↗
  27. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Co-author DOI 10.1038/s41586-018-0235-7↗
  28. The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship. Last author DOI 10.3390/cancers10090316↗
  29. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. Last author DOI 10.1371/journal.pone.0182855↗
  30. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment. Last author DOI 10.1158/1078-0432.ccr-15-2068↗
  31. Circulating tumor cells found in patients with localized and advanced pancreatic cancer. Co-author DOI 10.1097/mpa.0000000000000324↗
  32. Sonic Hedgehog in pancreatic cancer: from bench to bedside, then back to the bench. First author DOI 10.1016/j.surg.2012.05.030↗

Grants 3

  1. Epigenetic regulation of pancreatic cancer subtype identity and tumorigenesis by PHF2 R01CA272876↗
  2. Pancreatic cancer patient-derived xenograft tumors for translational studies in precision cancer medicine R01CA293063↗
  3. Epigenetic Regulation of Hemidesmosome Signaling in Pancreatic Cancer R03CA241971↗

Closest collaborators

The 25 strongest of 137 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ralph Weissleder · 2 shared papers, 1 shared grant, 2022–2026 · strength 1.68
  2. Andrew Louis Warshaw · 12 shared papers, 2015–2025 · strength 1.30
  3. Keith D. Lillemoe · 11 shared papers, 2015–2025 · strength 1.18
  4. David Tsai Ting · 9 shared papers, 2019–2025 · strength 1.01
  5. Carlos Fernández-del Castillo · 6 shared papers, 2019–2022 · strength 0.97
  6. Carlos F. Fernandez-del Castillo · 10 shared papers, 2015–2025 · strength 0.92
  7. Mari A. Mino-Kenudson · 9 shared papers, 2015–2025 · strength 0.86
  8. Thomas P. Hank · 5 shared papers, 2020–2025 · strength 0.61
  9. Kim C. Honselmann · 5 shared papers, 2017–2025 · strength 0.58
  10. Kazumichi Kawakubo · 2 shared papers, 2022 · strength 0.52
  11. David Jérémie Birnbaum · 4 shared papers, 2020–2022 · strength 0.46
  12. Sarah P. Thayer · 6 shared papers, 2012–2020 · strength 0.41
  13. Cristina Rosa Ferrone · 4 shared papers, 2020–2024 · strength 0.40
  14. Vikram Deshpande · 4 shared papers, 2019–2024 · strength 0.38
  15. Taisuke Baba · 2 shared papers, 2022–2025 · strength 0.37
  16. Ulrich Friedrich Wellner · 4 shared papers, 2019–2020 · strength 0.36
  17. François Bertucci · 3 shared papers, 2020–2022 · strength 0.35
  18. Jon Michael Harrison · 2 shared papers, 2024–2025 · strength 0.35
  19. Kenji Takahashi · 2 shared papers, 2022–2025 · strength 0.35
  20. Hiroki Sato · 2 shared papers, 2022–2025 · strength 0.35
  21. Hidemasa Kawabata · 2 shared papers, 2022–2025 · strength 0.35
  22. Yusuke Mizukami · 2 shared papers, 2022–2025 · strength 0.35
  23. Louisa Bolm · 2 shared papers, 2020–2025 · strength 0.33
  24. Sebastian K.S. Begg · 3 shared papers, 2020–2021 · strength 0.29
  25. Cristina R. Ferrone · 4 shared papers, 2017–2020 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.